Overview
- 21 FDA inspections are on record.
- 7 inspections produced a Form 483.
- The most recent recorded inspection date is 2026-04-02.
At a glance
Inspections
21
Form 483s
7
EIRs
1
Last outcome
Clean
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 30 Mar 2026 – 2 Apr 2026 | Human Drugs | Clean | |
| 21 Jul 2025 – 22 Jul 2025 | Tobacco Products | Clean | |
| 28 Nov 2023 – 7 Dec 2023 | Human Drugs | 483 | View 483 → |
| 15 Jul 2019 – 19 Jul 2019 | Human Drugs | 483 | View 483 → |
| 12 Jul 2017 – 20 Jul 2017 | Human Drugs | Clean | |
| 16 Mar 2017 – 31 Mar 2017 | Human Drugs | 483 | View 483 → |
| 15 Jun 2015 – 17 Jul 2015 | Human Drugs | WL | View 483 → |
| 30 Jun 2014 – 25 Jul 2014 | Human Drugs | 483 | View 483 → |
| 27 Jan 2012 | Not recorded | 483 | On file |
| 20 May 2011 | Not recorded | 483 | View 483 → |
| 30 Jun 2009 | Not recorded | Clean | |
| 10 Dec 2008 | Not recorded | Clean | |
Observations on record
Form 483 observations cited at this site, most recent first.
7 Dec 2023
21 CFR 314.81(b)(1)(ii)
Contamination, chemical or physical change, deterioration
Cited by Anastasia M Shields
7 Dec 2023
21 CFR 314.81(b)(1)(ii)
Contamination, chemical or physical change, deterioration
Cited by Anastasia M Shields
19 Jul 2019
21 CFR 211.194(a)
Complete test data included in records
Cited by Michael L Casner, Jaison J Eapen
Investigators
FDA investigators tied to this site in the record.
Gayle S Lawson5 insp.
Julianne C Mccullough2 insp.
Christina K Theodorou1 insp.
Harrison E Tandy1 insp.
Devon Jenkins1 insp.
Anastasia M Shields1 insp.
Michael L Casner1 insp.
Jaison J Eapen1 insp.
Craig D Zagata1 insp.
Lisa B Orr1 insp.
Sharon K Thoma1 insp.
Temar Q Williams1 insp.
Matthew R Noonan1 insp.
Stephen J Koniers1 insp.
Sam Pepe1 insp.
Denise M Digiulio1 insp.
Luella J Rossi1 insp.
Anita R Michael1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 6x |
| 21 CFR 314.81(b)(1)(ii) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 211.100(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.100(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.67(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.110(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.111 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.150(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.160(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.160(b)(1) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.165(f) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.166(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.166(a)(4) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.186(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.194(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.194(a)(1) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.22(d) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.63 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.67(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(1)(i) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Frontida BioPharm Inc's 7 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat